Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

@inproceedings{Ford2010ContinuousLI,
  title={Continuous long-term immunomodulatory therapy in relapsing multiple
                    sclerosis: results from the 15-year analysis of the US prospective open-label
                    study of glatiramer acetate},
  author={Corey Ford and A D Goodman and Karen Anne Johnson and Norman J Kachuck and J. William Lindsey and Robert P. Lisak and Christopher C Luzzio and L. W. Myers and Hillel S. Panitch and Jana Preiningerova and Amy A. Pruitt and John W. Rose and Horea G Rus and Jerry S. Wolinsky},
  booktitle={Multiple sclerosis},
  year={2010}
}
The ongoing US Glatiramer Acetate (GA) Trial is the longest evaluation of continuous immunomodulatory therapy in relapsing-remitting multiple sclerosis (RRMS). The objective of this study was to evaluate up to 15 years of GA as a sole disease-modifying therapy. Two hundred and thirty-two patients received at least one GA dose since study initiation in 1991 (mITT cohort), and 100 (43%, Ongoing cohort) continued as of February 2008. Patients were evaluated every 6 months using the Expanded… CONTINUE READING
Blog posts, news articles and tweet counts and IDs sourced by
Altmetric.com